Adam Koppel, Bain Capital managing director (William Penn Charter School via website)

Scoop: Adam Kop­pel's Bain team has an­oth­er $1.9B to wa­ger on life sci com­pa­nies. And he likes their odds

Adam Kop­pel filed his first Form D for his life sci­ences group at Bain al­most ex­act­ly 5 years ago. Af­ter jump­ing from a strat­e­gy post at Bio­gen, he had some clear ideas on ex­act­ly how he and his then-fledg­ling team at Bain Cap­i­tal Life Sci­ences would in­vest a siz­able amount of cap­i­tal in the in­dus­try.

He didn’t know it at the time, but it was ex­tra­or­di­nar­i­ly good tim­ing. Per­fect tim­ing for an in­dus­try that has been mak­ing land­mark ad­vances at the cen­ter of the world stage.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.